Background
To evaluate the persistence of seroprotection, anti-HBs titers, and anamnestic response to challenge dose, following the Brazilian Ministry of Health’s (MS) recommended HBV vaccination schedule in people living with HIV/AIDS (PLHIV).
Methods
Intervention study in PLHIV followed up in the outpatient clinics of the Infectious disease department at Federal University Hospital in Rio de Janeiro, who achieved seroprotection (anti-HBs ≥ 10mIU/mL) with the primary anti-HBV vaccination (4 doses of 40µg), in the original study between 2006-2010. In the current study (2021-2022), a blood sample was obtained prior to immunization, and one dose (40 µg) of the anti-HBV vaccine was administered shortly thereafter. A second sample was taken between one and six months after immunization. Seroprotection and antibody titers were assessed in both samples using commercial eletrochemiluminescence assays for HBsAg, anti-HBc and anti-HBs. Individuals who received additional doses of HBV vaccine during the period were excluded.
Results
75 of the 148 PLHIV in the original study participated (51%), 44% men, median interval between studies 14 years, age 53 years (36-75) and CD4 774 cells/mm³ (257-1936), 100% on ART and 99% with undetectable HIV viral load. In the pre-immunization sample, seroprotection was demonstrated in 80% of individuals with anti-HBs titers between 10-99 mIU/mL (33%); ≥100-999 mIU/mL (37%) and ≥1000 mIU/mL (10%). In post-immunization samples, seroprotection was demonstrated in 96% of individuals with anti-HBs titers between 10-99 mIU/mL (4%); ≥100-999 mIU/mL (12%) and ≥1000 mIU/mL (80%) (p<0.01). A significant decrease in anti-HBs titers was observed between studies (baseline and current, p<0.01) and a significant increase in titers between pre- and post-immunization samples (p<0.01). The time interval between the challenge dose and the post-immunization sample did not affect anti-HBs titers (p=0.62). Markers of HBV infection (anti-HBc and HBsAg) were non-reactive in all participants.
Conclusions
The scheme recommended by the Ministry of Health for vaccinating PLHIV against HBV resulted in sustained seroprotection for more than a decade. Even with the natural decline of antibodies, the use of a challenge dose was able to restore anti-HBs titers to the values obtained in the previous study. This ensures that it is the best scheme in the primary response to vaccination, and important in the generation of lasting immunologic memory.
Table or Figure